TransCode Therapeutics reports Phase 1a trial of TTX-MC138 meets safety endpoint in metastatic cancer

TransCode

TransCode

RNAZ

0.00
  • TransCode Therapeutics completed a Phase 1a dose-escalation trial of TTX-MC138 in metastatic cancer, clearing its safety objective.
  • Patients generally tolerated treatment, with no dose-limiting toxicities reported, supporting a move into Phase 2a development.
  • Several participants achieved durable disease stabilization, including some who remain on therapy.
  • Future scientific congress presentations are planned; a clinical study report is being prepared.
  • Phase 2a will evaluate TTX-MC138 in ctDNA-positive colorectal cancer following curative-intent therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE74261) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.